Target Trial Emulation: A Design Tool for Cancer Clinical Trials
JCO Clinical Cancer Informatics · 2023
DOI: 10.1200/cci.22.00140 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2023. Verfasst von Sandi A Kwee und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Queen's Medical Center, Honolulu, HI. Hauptthemen laut MEDLINE: Neoplasms, Randomized Controlled Trials as Topic, Research Design. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, AHRQ HHS.
Abstract (Originalsprache)
PURPOSE To apply target trial emulation to explore the potential impact of eligibility criteria on the primary outcome of a randomized controlled trial. METHODS Simulations of a real-world explanatory trial of transarterial radioembolization for advanced unresectable hepatocellular carcinoma with portal vein invasion were performed to examine the effects of cohort specification on survival outcomes and patient sample size. Simulations comprised 24 different permutations of the trial varied on three disease nonspecific eligibility parameters. Treatment and control arms for these emulated trials were drawn from the National Cancer Database and matched by treatment propensity. Target trial emulation served as the causal framework for this analysis, allowing the architecture of a true controlled experiment to address forms of bias routinely encountered in comparative effectiveness studies involving real-world observational data. RESULTS Twenty-four propensity score–matched cohorts comprising a wider clinical spectrum of patients than specified by the original target trial were successfully generated using the National Cancer Database. The arms for each of the emulated trials demonstrated exchangeability across all eligibility criteria and other clinical covariates. Significant treatment benefits were associated with only a narrow range of eligibility criteria, indicating that the original target trial was well specified. CONCLUSION The impact of patient selection on treatment outcomes can be studied using target trial emulation. This analytical framework can furthermore serve to leverage existing real-world data to inform the task of cohort specification for a randomized controlled trial, facilitating a more data-driven approach for this important step in clinical trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Queen's Medical Center, Honolulu, HI.
- University of Hawai`i Cancer Center, Clinical and Translational Sciences Program, University of Hawaii at Manoa, Honolulu, HI.
- Department of Surgery, The John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI.
- Indiana University School of Public Health, Bloomington, IN.
- The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI.
ORCID-Profile: Sandi A Kwee, Christina Ludema, Todd Seto
Förderung
- NCI NIH HHS
- AHRQ HHS
Zitieren
APA
Kwee, S. A., Wong, L. L., Ludema, C., Deng, C. K., Taira, D., Seto, T., & Landsittel, D. (2023). Target Trial Emulation: A Design Tool for Cancer Clinical Trials. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.22.00140
Vancouver
Kwee SA, Wong LL, Ludema C, Deng CK, Taira D, Seto T, et al. Target Trial Emulation: A Design Tool for Cancer Clinical Trials. JCO Clinical Cancer Informatics. 2023. doi:10.1200/cci.22.00140
BibTeX
@article{Kwee2023,
author = {Kwee, Sandi A and Wong, Linda L and Ludema, Christina and Deng, Chris K and Taira, Deborah and Seto, Todd and Landsittel, Douglas},
title = {Target Trial Emulation: A Design Tool for Cancer Clinical Trials},
journal = {JCO Clinical Cancer Informatics},
year = {2023},
doi = {10.1200/cci.22.00140}
}
EUVIMED